Drug profile · INN
dabigatran etexilate mesylate
DABIGATRAN ETEXILATE MESYLATE
dabigatran etexilate mesylate (DABIGATRAN ETEXILATE MESYLATE) is a thrombin inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — dabigatran etexilate mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
dabigatran etexilate mesylate (DABIGATRAN ETEXILATE MESYLATE) is a thrombin inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombin inhibitor
Primary target: Prothrombin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dabigatran etexilate mesylate?
dabigatran etexilate mesylate (DABIGATRAN ETEXILATE MESYLATE) is a thrombin inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dabigatran etexilate mesylate?
DABIGATRAN ETEXILATE MESYLATE is a marketed brand name for dabigatran etexilate mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dabigatran etexilate mesylate?
dabigatran etexilate mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.